# ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

> **NCT06332170** · PHASE1 · RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 610 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** HS-20093
- **DRUG:** Adebrelimab
- **DRUG:** Cisplatin/ Carboplatin
- **DRUG:** Cetuximab
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT06332170
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-26
- **Primary completion:** 2026-05-30
- **Final completion:** 2028-05-30
- **Target enrollment:** 610 (ESTIMATED)
- **Last updated:** 2024-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06332170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06332170, "ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06332170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*